All conditions

Crohn's Disease and Colitis

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

102
Trials tracked
8
Recruiting now
56
Australian sites
66
Countries
Country

Showing 102 trials

🇦🇺 AU site

Trial: NCT03466411 — Janssen Research & Development, LLC

NCT03466411 · Janssen Research & Development, LLC
Active, Not Recruiting Phase 3 Est. completion 20 October 2023
🇦🇺 AU 🇦🇹 AT Belarus 🇧🇪 BE Bosnia and Herzegovina

Who might be able to join this trial: - You have been diagnosed with Crohn's disease (including a form that causes tunnels or passages called fistulas) for at least 3 months, affecting your colon, small intestine, or both, confirmed at some...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT05242471 — Janssen Research & Development, LLC

NCT05242471 · Janssen Research & Development, LLC
Active, Not Recruiting Phase 2 Est. completion 23 May 2025
🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR 🇧🇬 BG

Who might be able to join this trial: - You have been diagnosed with Crohn's disease for at least 3 months before the start of the trial - Your Crohn's disease has been confirmed as moderate to severe (confirm with trial site for how this i...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01393626 — Pfizer

NCT01393626 · Pfizer
Completed Phase 2 Est. completion 1 February 2015
🇦🇺 AU 🇦🇹 AT 🇧🇬 BG 🇨🇦 CA 🇭🇷 HR

Who might be able to join this trial: - You are between 18 and 75 years old (note: the upper age limit is 64 in India and 65 in the Netherlands) - You have been diagnosed with Crohn's disease for at least 6 months before the screening visit...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03440385 — Celgene

NCT03440385 · Celgene
Completed Phase 3 Est. completion 21 November 2023
🇦🇺 AU 🇦🇹 AT 🇧🇬 BG 🇨🇦 CA 🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with Crohn's disease for at least 3 months, confirmed by a camera examination of the gut (endoscopy) and tissue sample (biopsy) - Previous treatments have not worked well e...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03926130 — Eli Lilly and Company

NCT03926130 · Eli Lilly and Company
Completed Phase 3 Est. completion 23 August 2023
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR

**Who might be able to join this trial:** - You have been diagnosed with Crohn's disease for at least 3 months before the start of the trial. - Your Crohn's disease has been confirmed as moderate to severe, based on specific medical assessm...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01090817 — R.P.Herrmann

NCT01090817 · R.P.Herrmann
Completed Phase 2 Est. completion 1 June 2014
🇦🇺 AU

**Who might be able to join this trial:** - You have Crohn's disease affecting the large bowel (colon) or small bowel, confirmed by camera examination (endoscopy) and tissue samples (biopsy) - You have tried the biologic medicines inflixima...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00552058 — UCB Pharma

NCT00552058 · UCB Pharma
Completed Phase 3 Est. completion 1 October 2009
🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR 🇨🇦 CA

Who might be able to join this trial: - You can be either male or female - You must be between 18 and 75 years old (inclusive) - You have been officially diagnosed with Crohn's disease - Your Crohn's disease is currently considered moderate...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03345849 — AbbVie

NCT03345849 · AbbVie
Completed Phase 3 Est. completion 15 October 2021
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE Bosnia and Herzegovina

**Who might be able to join this trial:** - You have been diagnosed with Crohn's disease (CD) for at least 3 months before the study starts. - Your Crohn's disease has been confirmed as moderate to severe, based on how often you have bowel...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01951326 — RedHill Biopharma Limited

NCT01951326 · RedHill Biopharma Limited
Completed Phase 3 Est. completion 1 May 2018
🇦🇺 AU 🇧🇬 BG 🇨🇦 CA 🇨🇿 CZ 🇮🇱 IL

**Who might be able to join this trial:** - You are willing and able to sign a consent form to take part in the study. - You have been diagnosed with Crohn's Disease, confirmed by a scope, scan, or tissue sample, at least 6 months before j...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00989560 — University of Melbourne

NCT00989560 · University of Melbourne
Completed Phase 3 Est. completion 1 April 2013
🇦🇺 AU

Who might be able to join this trial: - You have been diagnosed with Crohn's disease and have a confirmed history of the condition - You have had surgery to remove part of your bowel, where the remaining ends were joined back together Who...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00206674 — Genzyme, a Sanofi Company

NCT00206674 · Genzyme, a Sanofi Company
Completed Phase 3 Est. completion 1 June 2006
🇦🇷 AR 🇦🇺 AU 🇧🇷 BR 🇨🇦 CA 🇳🇿 NZ

Who might be able to join this trial: - You have Crohn's disease that is active (causing symptoms) but in a stable condition at the time of screening - You are able to give yourself an injection, or you have someone who can help you do this...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00160524 — UCB Pharma SA

NCT00160524 · UCB Pharma SA
Completed Phase 3 Est. completion 1 August 2012
🇦🇺 AU 🇦🇹 AT Belarus 🇧🇪 BE 🇧🇬 BG

Who might be able to join this trial: - You must have already taken part in one of two specific earlier studies (called CDP870-031 or CDP870-032) and completed it at the 26-week point, whether you received the active treatment, a dummy trea...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01233960 — Mesoblast, Inc.

NCT01233960 · Mesoblast, Inc.
Completed Phase 3 Est. completion 15 September 2014
🇦🇺 AU 🇳🇿 NZ 🇺🇸 US

**Who might be able to join this trial:** - You must have already joined and signed consent forms for a related earlier study called "Protocol 603" after August 3, 2010. - You must have completed all the required check-up and screening step...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01287897 — Pfizer

NCT01287897 · Pfizer
Completed Phase 2 Est. completion 1 September 2014
🇦🇺 AU 🇧🇪 BE 🇧🇷 BR 🇨🇦 CA 🇨🇿 CZ

Here is the eligibility information in plain English: **Who might be able to join this trial:** - You have tried anti-TNF medications (a type of treatment for inflammatory conditions) but they did not work for you, or you were unable to to...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site
Completed Phase 2 Est. completion 23 September 2022
🇦🇺 AU 🇧🇪 BE 🇨🇦 CA 🇨🇿 CZ 🇫🇷 FR

**Who might be able to join this trial:** - You have a confirmed diagnosis of Crohn's disease (CD) - Your Crohn's disease is considered moderately to severely active, based on a specific activity score and a camera examination of your bowe...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT02394028 — Hoffmann-La Roche

NCT02394028 · Hoffmann-La Roche
Completed Phase 3 Est. completion 7 September 2021
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR

**Who might be able to join this trial:** - You have been diagnosed with moderately to severely active Crohn's Disease, confirmed through symptom scoring, patient-reported symptoms, and a camera examination (endoscopy) of the small intesti...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00771667 — Centocor, Inc.

NCT00771667 · Centocor, Inc.
Completed Phase 2 Est. completion 1 May 2010
🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇨🇦 CA 🇫🇷 FR

Who might be able to join this trial: - You have been diagnosed with Crohn's disease (including a type involving abnormal tunnels called fistulas) for at least 3 months. - You have previously been treated with at least one of these medicati...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT02367183 — Celgene

NCT02367183 · Celgene
Completed Phase 1 Est. completion 6 September 2016
🇦🇺 AU 🇨🇦 CA 🇭🇺 HU 🇸🇰 SK 🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older. - You are willing and able to understand and sign a consent form before any study activities begin. - You are able to attend all required study visits and follow th...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01345318 — Pfizer

NCT01345318 · Pfizer
Completed Phase 2 Est. completion 1 March 2016
🇦🇺 AU 🇧🇪 BE 🇧🇷 BR 🇨🇦 CA 🇨🇿 CZ

**Who might be able to join this trial:** - You must have already taken part in a previous related study (called B0151003) and completed the first 12 weeks (84 days) of that study. - You must be willing and able to attend scheduled appointm...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03283085 — Shire

NCT03283085 · Shire
Completed Phase 3 Est. completion 13 December 2023
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE Bosnia and Herzegovina

**Who might be able to join this trial:** **If you have Ulcerative Colitis (UC):** - You (or your parent or legal representative) are willing and able to fully follow all study rules and procedures. - You (or your parent or legal represent...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01369329 — Janssen Research & Development, LLC

NCT01369329 · Janssen Research & Development, LLC
Completed Phase 3 Est. completion 1 June 2013
🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR 🇨🇦 CA

**Who might be able to join this trial:** - You have been diagnosed with Crohn's disease for at least 3 months, affecting your colon, small intestine, or both, confirmed at some point by imaging, tissue testing, or a camera examination of t...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00195715 — Abbott

NCT00195715 · Abbott
Completed Phase 3 Est. completion 1 March 2006
🇦🇺 AU 🇧🇪 BE 🇨🇦 CA 🇩🇰 DK 🇫🇷 FR

Who might be able to join this trial: - You must have already successfully completed one of two specific earlier clinical trials (called M02-404 or M04-691) to be eligible for this study - You have been diagnosed with Crohn's disease - You...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04018040 — Edith Cowan University

NCT04018040 · Edith Cowan University
Completed Not Applicable Est. completion 10 August 2023
🇦🇺 AU

**Who might be able to join this trial:** - You are able to give your own consent to take part in the study - You are 18 years of age or older - You have been diagnosed with ulcerative colitis or Crohn's disease for more than 3 months, con...

🇦🇺 AU site

Trial: NCT02624414 — Melbourne Health

NCT02624414 · Melbourne Health
Completed Not Applicable Est. completion 31 December 2020
🇦🇺 AU

**Who might be able to join this trial:** - Adults between 18 and 75 years old (both men and women) who have already been diagnosed with Crohn's disease affecting the small intestine, large intestine, or both - Patients who are seen at the...

🇦🇺 AU site

Trial: NCT04877990 — Bristol-Myers Squibb

NCT04877990 · Bristol-Myers Squibb
Completed Phase 2 Est. completion 29 August 2023
🇦🇺 AU 🇨🇦 CA 🇨🇳 CN 🇩🇪 DE 🇭🇺 HU

**Who might be able to join this trial:** - You must have already taken part in and completed a previous related study (called a "parent study") for Crohn's disease or ulcerative colitis, where the treatment was given in an open, non-blinde...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT02611817 — Takeda

NCT02611817 · Takeda
Completed Phase 3 Est. completion 6 May 2019
🇦🇺 AU 🇧🇪 BE Bosnia and Herzegovina 🇧🇷 BR 🇧🇬 BG

**Who might be able to join this trial:** - You were diagnosed with Crohn's disease (CD) at least 3 months before the study screening, confirmed by a camera examination of the gut and a tissue sample analysis. - Your Crohn's disease is mod...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT07079007 — Austin Health

NCT07079007 · Austin Health
Not Yet Recruiting Not Applicable Est. completion 1 November 2025
🇦🇺 AU

Who might be able to join this trial: - You have been diagnosed with, or are suspected to have, Crohn's disease that affects the small bowel - A scan has shown that the wall of the last part of your small intestine (called the terminal ileu...

🇦🇺 AU site

Trial: NCT05442567 — Takeda

NCT05442567 · Takeda
Recruiting Phase 3 Est. completion 7 February 2033
🇦🇺 AU 🇧🇪 BE 🇨🇦 CA 🇨🇳 CN 🇭🇷 HR

**Who might be able to join this trial:** **Treatment Group:** - You completed one of two specific earlier studies (MLN0002-3024 or MLN0002-3025) and your condition improved enough — without needing steroids — by Week 54 of that study (mee...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04970446 — St Vincent's Hospital Melbourne

NCT04970446 · St Vincent's Hospital Melbourne
Recruiting Phase 2 Est. completion 1 April 2025
🇦🇺 AU

**Who might be able to join this trial:** - You have been diagnosed with active Crohn's disease that has been confirmed by a camera test (endoscopy) showing active inflammation within the last 6 months — or, if your disease is in a part of...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06226883 — Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

NCT06226883 · Morphic Therapeutic, Inc. (A Wholly Owned Subsidia...
Recruiting Phase 2 Est. completion 1 September 2028
🇦🇺 AU 🇦🇹 AT Bosnia and Herzegovina 🇧🇷 BR 🇧🇬 BG

**Who might be able to join this trial:** - You have had signs or symptoms of Crohn's disease (CD) for at least 90 days before the screening visit. - Your Crohn's disease is considered moderately to severely active, based on a specific sco...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06430801 — Merck Sharp & Dohme LLC

NCT06430801 · Merck Sharp & Dohme LLC
Recruiting Phase 3 Est. completion 30 October 2028
🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR 🇨🇦 CA

**Who might be able to join this trial:** - You have been diagnosed with Crohn's disease (CD) for at least 3 months before joining the study. - Your Crohn's disease is considered moderately to severely active. - Previous treatments have not...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06819891 — Hoffmann-La Roche

NCT06819891 · Hoffmann-La Roche
Recruiting Phase 3 Est. completion 31 December 2028
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR

**Who might be able to join this trial:** - You have been officially diagnosed with Crohn's disease (CD) - Your Crohn's disease is considered moderately to severely active - You weigh at least 40 kilograms (about 88 pounds) - Previous trea...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT05923073 — Janssen Research & Development, LLC

NCT05923073 · Janssen Research & Development, LLC
Recruiting Phase 3 Est. completion 27 October 2027
🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR 🇨🇦 CA

**Who might be able to join this trial:** - You (or your child) must have been diagnosed with Crohn's Disease (including a type that causes tunnels or tracts, called fistulizing Crohn's Disease), affecting the large intestine, small intest...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06257706 — Alimentiv Inc.

NCT06257706 · Alimentiv Inc.
Recruiting Phase 4 Est. completion 3 January 2029
🇦🇺 AU 🇧🇪 BE 🇨🇦 CA 🇨🇿 CZ 🇩🇰 DK

**Who might be able to join this trial:** - You are between 18 and 80 years old - You have moderately to severely active Crohn's disease, based on specific scoring measurements your doctor uses to assess disease activity (confirm with tria...

Phase 4: Approved of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06663332 — Janssen Research & Development, LLC

NCT06663332 · Janssen Research & Development, LLC
Recruiting Phase 3 Est. completion 12 December 2031
🇦🇷 AR 🇦🇺 AU 🇧🇷 BR 🇨🇳 CN 🇫🇷 FR

**Who might be able to join this trial:** - You must have already completed all planned doses in the original pediatric guselkumab study. - The study doctor must believe that you are still benefiting from continuing guselkumab treatment. -...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00562887 — Abbott

NCT00562887 · Abbott
Terminated Phase 2 Est. completion 1 April 2010
🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇨🇦 CA 🇩🇰 DK

**Who might be able to join this trial:** - You have been diagnosed with Crohn's disease for more than 4 months, confirmed by a camera examination of the gut or an imaging scan. - Your Crohn's disease activity falls within a specific range...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01536418 — GlaxoSmithKline

NCT01536418 · GlaxoSmithKline
Terminated Phase 3 Est. completion 17 October 2013
🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇬 BG 🇨🇦 CA

**Who might be able to join this trial:** - You are 18 years of age or older - You are willing and able to give written consent before any screening procedures begin - You have been diagnosed with Crohn's disease for more than 4 months, af...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00206700 — Genzyme, a Sanofi Company

NCT00206700 · Genzyme, a Sanofi Company
Terminated Phase 2 Est. completion 1 December 2006
🇦🇷 AR 🇦🇺 AU 🇧🇷 BR 🇨🇦 CA 🇳🇿 NZ

**Who might be able to join this trial:** - You are able to give your consent to take part in the study - You took part in a previous study of the drug sargramostim for Crohn's disease within the last 12 months - If your previous study did...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00295165 — Genzyme, a Sanofi Company

NCT00295165 · Genzyme, a Sanofi Company
Terminated Phase 3 Est. completion 1 October 2006
🇦🇺 AU 🇧🇷 BR 🇧🇬 BG 🇨🇦 CA 🇮🇱 IL

**Who might be able to join this trial:** - You are 18 years old or older - You have been officially diagnosed with Crohn's disease (confirmed by a camera exam of the gut or an imaging scan) for at least 4 months before starting the study...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT05068284 — AbbVie

NCT05068284 · AbbVie
Terminated Phase 2 Est. completion 20 July 2023
🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇬 BG 🇨🇦 CA

**Who might be able to join this trial:** - You have been diagnosed with Crohn's Disease for at least 3 months before the study starts. - Your Crohn's Disease activity falls within a certain range of severity, based on a standard scoring s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT02403323 — Hoffmann-La Roche

NCT02403323 · Hoffmann-La Roche
Terminated Phase 3 Est. completion 9 October 2023
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR

Who might be able to join this trial: - You previously took part in a related etrolizumab study (called GA29144 / NCT02394028) and meet the requirements to continue receiving the open-label treatment in Part 1 of this trial - You took part...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03464097 — Celgene

NCT03464097 · Celgene
Terminated Phase 3 Est. completion 3 October 2024
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT Belarus 🇧🇪 BE

**Who might be able to join this trial:** - You met the requirements to join the earlier part of this study (called the "induction study") and completed all required assessments at the 12-week mark. - At week 12 of the induction study, you...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03635112 — Theravance Biopharma

NCT03635112 · Theravance Biopharma
Terminated Phase 2 Est. completion 30 December 2021
🇦🇺 AU 🇦🇹 AT 🇧🇬 BG 🇭🇷 HR 🇫🇷 FR

Who might be able to join this trial: - You are at least 18 years old at the time of screening - You are male or female and have been diagnosed with Crohn's disease for at least 3 months before screening - Your Crohn's disease is considered...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT02743806 — Takeda

NCT02743806 · Takeda
Terminated Phase 4 Est. completion 3 January 2023
🇦🇺 AU 🇧🇬 BG 🇨🇿 CZ 🇪🇪 EE 🇭🇺 HU

**Who might be able to join this trial:** - You previously received vedolizumab (not a placebo or comparison drug) as part of an earlier qualifying clinical study. - Your doctor believes you are still benefiting from vedolizumab and that co...

Phase 4: Approved of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03218202 — St Vincent's Hospital Melbourne

NCT03218202 · St Vincent's Hospital Melbourne
Terminated Not Applicable Est. completion 29 August 2019
🇦🇺 AU

**Who might be able to join this trial:** - You have inflammatory bowel disease (such as Crohn's disease or ulcerative colitis) and have been found to have a narrowing in your intestine (called a stricture) on a scan or camera test, but thi...

🇦🇺 AU site

Trial: NCT05470985 — Bristol-Myers Squibb

NCT05470985 · Bristol-Myers Squibb
Terminated Phase 3 Est. completion 13 September 2024
🇦🇺 AU 🇧🇪 BE 🇨🇦 CA 🇫🇷 FR 🇩🇪 DE

**Who might be able to join this trial:** - Your child's Crohn's disease must be rated as moderately to severely active based on a specific symptom score (called PCDAI), AND a camera examination of the gut (called an endoscopy) must show a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01316939 — GlaxoSmithKline

NCT01316939 · GlaxoSmithKline
Terminated Phase 3 Est. completion 23 October 2013
🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇬 BG 🇨🇦 CA

**Who might be able to join this trial:** - You must have already taken part in a related induction study (Study CCX114151 or another GSK-sponsored study) and shown improvement in your Crohn's disease symptoms or reached remission during t...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03597971 — Nutrition Science Partners Limited

NCT03597971 · Nutrition Science Partners Limited
Terminated Phase 1 Est. completion 19 November 2018
🇦🇺 AU

**Who might be able to join this trial:** - You must be willing and able to sign a written consent form before joining the study - You must be a healthy male between 18 and 45 years old at the time of screening - Your body mass index (BMI)...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03559517 — Shire

NCT03559517 · Shire
Terminated Phase 3 Est. completion 7 July 2020
🇦🇺 AU 🇦🇹 AT 🇭🇷 HR 🇩🇪 DE 🇮🇱 IL

**Who might be able to join this trial:** - You are between 16 and 80 years old (if you are under 18, you must also weigh at least 40 kg and have a body mass index of at least 16.5) - You have been diagnosed with moderate to severe Crohn's...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01190839 — Janssen Biotech, Inc.

NCT01190839 · Janssen Biotech, Inc.
Terminated Phase 3 Est. completion 1 December 2014
🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇨🇦 CA 🇨🇿 CZ

**Who might be able to join this trial:** - You have been officially diagnosed with Crohn's disease, confirmed through camera examinations of the gut, tissue samples, and/or imaging scans before or during surgery - You have had surgery to r...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04173273 — Pfizer

NCT04173273 · Pfizer
Terminated Phase 3 Est. completion 23 April 2025
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT Belarus 🇧🇪 BE

**Who might be able to join this trial:** - You are a man or woman between 18 and 80 years old - You are able to give written consent and are able to follow the schedule of visits and assessments required by the trial - You have been diagno...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03599622 — Bristol-Myers Squibb

NCT03599622 · Bristol-Myers Squibb
Terminated Phase 2 Est. completion 12 December 2022
🇦🇺 AU 🇧🇪 BE 🇧🇷 BR 🇨🇦 CA 🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with Crohn's Disease for at least 3 months before the screening visit, affecting the small intestine, large intestine, or both - You have tried one or more standard treatme...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT02641392 — Celgene

NCT02641392 · Celgene
Terminated Phase 3 Est. completion 4 January 2018
🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇬 BG 🇨🇦 CA

**Who might be able to join this trial:** - You are 18 years of age or older (for adult participants) - You previously took part in a specific related clinical study called GED-0301-CD-002 or GED-0301-CD-003 - You are willing and able to u...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03467958 — Celgene

NCT03467958 · Celgene
Terminated Phase 3 Est. completion 31 October 2024
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT Belarus 🇧🇪 BE

**Who might be able to join this trial:** - You did not fully respond to (or achieve remission from) a related induction study after 12 weeks of treatment - You experienced a return of symptoms (relapse) during or after completing a related...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03220841 — St Vincent's Hospital Melbourne

NCT03220841 · St Vincent's Hospital Melbourne
UNKNOWN Phase 4 Est. completion 18 September 2020
🇦🇺 AU

**Who might be able to join this trial:** - You have been diagnosed with inflammatory bowel disease (such as Crohn's disease or ulcerative colitis) and have one or more narrowings (strictures) in your intestine that were found on a CT scan,...

Phase 4: Approved of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03477032 — St Vincent's Hospital Melbourne

NCT03477032 · St Vincent's Hospital Melbourne
UNKNOWN Not Applicable Est. completion 31 December 2019
🇦🇺 AU

**Who might be able to join this trial:** - You have been diagnosed with Crohn's disease, Ulcerative Colitis, or Microscopic Colitis, confirmed through scans, camera tests (endoscopy), or tissue samples. - Your condition is currently activ...

Trial: NCT04488198 — Medical University of Vienna

NCT04488198 · Medical University of Vienna
Active, Not Recruiting Not Applicable Est. completion 31 December 2026
🇦🇹 AT

Who might be able to join this trial: - You have a mild or moderate form of chronic inflammatory bowel disease (a long-term condition causing inflammation in the digestive system) - Your current medication for this condition has remained th...

Trial: NCT06681181 — GlaxoSmithKline

NCT06681181 · GlaxoSmithKline
Active, Not Recruiting Phase 1 Est. completion 23 April 2026
🇬🇧 GB

**Who might be able to join this trial:** - You are generally in good health, based on a full medical check-up including blood tests and heart monitoring - Your white blood cell counts (including two specific types: lymphocytes and neutrop...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT04283864 — Weizmann Institute of Science

NCT04283864 · Weizmann Institute of Science
Active, Not Recruiting Not Applicable Est. completion 1 December 2026
🇮🇱 IL 🇮🇹 IT

**Who might be able to join this trial:** - Children aged 6 to 18 years who are suspected of having Crohn's disease (CD) and have not yet started any medical or nutritional treatment - Children aged 6 to 18 years who have been diagnosed wi...

Trial: NCT02851134 — University Hospital, Lille

NCT02851134 · University Hospital, Lille
Completed Not Applicable Est. completion 1 April 2018
🇫🇷 FR

Who might be able to join this trial: - You have been diagnosed with Crohn's disease - You are part of a family registered in the EPIMAD database that has at least 3 members diagnosed with Crohn's disease Who may not be able to join: - Wom...

Trial: NCT03574948 — University Hospital, Ghent

NCT03574948 · University Hospital, Ghent
Completed Phase 2 Est. completion 23 February 2021
🇧🇪 BE

**Who might be able to join this trial:** - You are between 18 and 60 years old (inclusive) - You have been diagnosed with Crohn's disease or ulcerative colitis - Your doctor believes you are able to understand and follow the study requirem...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT02539368 — Pfizer

NCT02539368 · Pfizer
Completed Not Applicable Est. completion 31 October 2018
🇧🇪 BE 🇨🇿 CZ 🇫🇮 FI 🇫🇷 FR 🇩🇪 DE

**Who might be able to join this trial:** - You were at least 12 years old when you were first diagnosed with Crohn's disease (CD) or ulcerative colitis (UC), and you are at least 18 years old at the time of joining the study. - Your doctor...

Trial: NCT02883296 — Central Hospital, Nancy, France

NCT02883296 · Central Hospital, Nancy, France
Completed Not Applicable Est. completion 1 June 2014

**Who might be able to join this trial:** - You are willing and able to participate, and can give written consent - You have been diagnosed with Crohn's disease, confirmed through medical tests such as blood work, endoscopy, imaging, or cli...

Trial: NCT00917514 — Medicpen AB

NCT00917514 · Medicpen AB
Completed Not Applicable Est. completion 1 February 2010
🇸🇪 SE

Who might be able to join this trial: - You can be either male or female - You must be 18 years old or older - You must be willing and able to sign a consent form agreeing to take part in the study - You must have been diagnosed with Crohn'...

Trial: NCT01183403 — Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

NCT01183403 · Groupe d'Etude Therapeutique des Affections Inflam...
Completed Not Applicable Est. completion 1 July 2012
🇧🇪 BE 🇫🇷 FR

**Who might be able to join this trial:** - You have been diagnosed with Crohn's disease, confirmed through camera tests (endoscopy), imaging, or tissue samples - You have a narrowing (stricture) in the small bowel (in the part called the j...

Trial: NCT00805766 — Tanabe Pharma Corporation

NCT00805766 · Tanabe Pharma Corporation
Completed Phase 3 Est. completion 1 November 2009
🇯🇵 JP

**Who might be able to join this trial:** - You have been diagnosed with Crohn's disease - Your Crohn's disease symptoms have come back within the last 8 weeks, even though you have been taking a regular maintenance dose of REMICADE (inflix...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00305409 — University of Dundee

NCT00305409 · University of Dundee
Completed Not Applicable Est. completion 1 December 2008
🇬🇧 GB

Who might be able to join this trial: - You have been diagnosed with Crohn's disease affecting the large bowel (with or without involvement of the small bowel) - You are between 18 and 79 years old - You have been on the same doses of your...

Trial: NCT04940611 — Takeda

NCT04940611 · Takeda
Completed Not Applicable Est. completion 30 April 2025
🇦🇹 AT 🇧🇪 BE 🇨🇦 CA 🇨🇿 CZ 🇫🇷 FR

**Who might be able to join this trial:** - You have a complex anal fistula related to Crohn's disease (a type of inflammatory bowel condition) that is classified as a certain type based on its location or complexity (such as being deep, h...

Trial: NCT02185183 — Hadassah Medical Organization

NCT02185183 · Hadassah Medical Organization
Completed Phase 2 Est. completion 1 January 2010

Who might be able to join this trial: - You have been diagnosed with Crohn's disease (a type of inflammatory bowel condition) Who may not be able to join: - You are currently taking medications or have a condition that weakens or suppresse...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01316601 — Gerhard Rogler

NCT01316601 · Gerhard Rogler
Completed Phase 2 Est. completion 1 November 2012
🇨🇭 CH

Who might be able to join this trial: - You have been diagnosed with Crohn's disease for more than 6 months and have a fistula (an abnormal tunnel or opening that forms between body parts) - You have tried at least one treatment for your fi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03508193 — Dale Lee

NCT03508193 · Dale Lee
Completed Not Applicable Est. completion 5 January 2022
🇺🇸 US

**Who might be able to join this trial:** - You are between 8 and 21 years old - You have been diagnosed with Crohn's disease within the last 4 weeks - Your Crohn's disease is currently active, based on a standard activity score used for ch...

Trial: NCT02709694 — Hospital for Special Surgery, New York

NCT02709694 · Hospital for Special Surgery, New York
Completed Not Applicable Est. completion 1 January 2019
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with Crohn's Disease confirmed by a biopsy. - You either do or do not have back pain that is related to inflammation (the trial is looking for a mix of both groups). - You are...

Trial: NCT01959087 — Assistance Publique - Hôpitaux de Paris

NCT01959087 · Assistance Publique - Hôpitaux de Paris
Completed Not Applicable Est. completion 24 February 2017
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years of age or older - You are having part of your colon (large intestine) removed because of a non-cancerous or cancerous growth, Crohn's disease, or diverticulitis (a condition affec...

Trial: NCT03773237 — Mayo Clinic

NCT03773237 · Mayo Clinic
Completed Not Applicable Est. completion 1 December 2023
🇺🇸 US

**Who might be able to join this trial:** - You are a new patient starting home parenteral nutrition (nutrition delivered through a vein at home) through Mayo Clinic - You are able to understand and sign a consent form agreeing to take part...

Trial: NCT04538638 — Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

NCT04538638 · Academisch Medisch Centrum - Universiteit van Amst...
Completed Not Applicable Est. completion 1 May 2023
🇳🇱 NL

**Who might be able to join this trial:** - You have Crohn's disease affecting the end of the small bowel and the start of the large bowel, and your doctors have recommended surgery to remove that section. - You are currently taking medicat...

Trial: NCT02255370 — University Hospital, Clermont-Ferrand

NCT02255370 · University Hospital, Clermont-Ferrand
Completed Phase 3 Est. completion 1 November 2017
🇫🇷 FR

**Who might be able to join this trial:** - You have been diagnosed with Crohn's disease, confirmed through imaging, a camera procedure (such as a colonoscopy), or a tissue sample examination - You are over 18 years old - You are covered by...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00329550 — UCB Japan Co. Ltd.

NCT00329550 · UCB Japan Co. Ltd.
Completed Phase 2 Est. completion 1 April 2008
🇯🇵 JP

Who might be able to join this trial: - You took part in a previous related clinical trial (called study C87037 or NCT00291668) and your Crohn's disease symptoms improved during that study. Who may not be able to join: - You took part in t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01676324 — University of British Columbia

NCT01676324 · University of British Columbia
Completed Not Applicable Est. completion 1 March 2013
🇨🇦 CA

Who might be able to join this trial: - You must be 19 years of age or older - You must be able to read and sign a consent form written in English - You have stomach or digestive symptoms, or you have already been diagnosed with Inflammator...

Trial: NCT02186275 — St. Justine's Hospital

NCT02186275 · St. Justine's Hospital
Completed Phase 3 Est. completion 20 December 2019
🇨🇦 CA

**Who might be able to join this trial:** - You have been diagnosed with Crohn's disease, confirmed through clinical assessments, a camera examination of the gut, and tissue samples - You are between 9 and 18 years old at the time of joinin...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00374374 — Odense University Hospital

NCT00374374 · Odense University Hospital
Completed Not Applicable
🇩🇰 DK

**Who might be able to join this trial:** - You have previously been diagnosed with Crohn's disease affecting the large bowel, or both the large and small bowel - You have had at least one flare-up or active episode of Crohn's disease in th...

Trial: NCT00206596 — Genzyme, a Sanofi Company

NCT00206596 · Genzyme, a Sanofi Company
Completed Phase 2 Est. completion 1 October 2005

Who might be able to join this trial: - You have been diagnosed with Crohn's disease within the last 6 months and the disease is currently active. - You have been taking between 10–40 mg per day of prednisone (a steroid) for more than 3 mon...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01442025 — Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

NCT01442025 · Groupe d'Etude Therapeutique des Affections Inflam...
Completed Phase 4 Est. completion 1 July 2015
🇫🇷 FR

**Who might be able to join this trial:** - You are over 18 years old - You have active Crohn's disease with visible ulcers seen on a camera test (endoscopy), plus blood or stool test results showing active inflammation - You have never pre...

Phase 4: Approved of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT06069167 — Paris IBD Center

NCT06069167 · Paris IBD Center
Completed Not Applicable Est. completion 22 March 2024
🇫🇷 FR

Who might be able to join this trial: - You are at least 18 years old (male or female) - You have been diagnosed with inflammatory bowel disease (such as Crohn's disease or ulcerative colitis) for at least 3 months, based on recognised Euro...

Trial: NCT01331551 — Harvard School of Public Health (HSPH)

NCT01331551 · Harvard School of Public Health (HSPH)
Completed Not Applicable Est. completion 1 August 2018
🇺🇸 US

Here is the eligibility information explained in plain language: **Who might be able to join this trial:** - You are currently taking a medication called mesalamine, and you are willing to switch to a different brand of it for 4 months (or...

Trial: NCT02508012 — University Hospital, Montpellier

NCT02508012 · University Hospital, Montpellier
Completed Not Applicable Est. completion 1 January 2020
🇫🇷 FR

Who might be able to join this trial: - You have been diagnosed with Crohn's disease or ulcerative colitis - You are currently being treated with an anti-TNF medication (a type of drug that reduces inflammation by blocking a protein called...

Trial: NCT00277251 — Boston Children's Hospital

NCT00277251 · Boston Children's Hospital
Completed Phase 3 Est. completion 1 June 2006

**Who might be able to join this trial:** - You have been diagnosed with one of these conditions: ulcerative colitis, Crohn's disease, systemic-onset juvenile rheumatoid arthritis, juvenile dermatomyositis, lupus (SLE), mixed connective ti...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03107793 — Janssen-Cilag Ltd.

NCT03107793 · Janssen-Cilag Ltd.
Completed Phase 3 Est. completion 30 April 2020
🇧🇪 BE 🇨🇿 CZ 🇩🇰 DK 🇫🇷 FR 🇩🇪 DE

**Who might be able to join this trial:** - You have active, moderate to severe Crohn's disease affecting the small intestine and/or colon, confirmed by a symptom score and a camera examination (endoscopy) showing signs of active disease -...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03733314 — EA Pharma Co., Ltd.

NCT03733314 · EA Pharma Co., Ltd.
Completed Phase 2 Est. completion 16 March 2022
🇨🇿 CZ 🇭🇺 HU 🇯🇵 JP 🇵🇱 PL 🇷🇺 RU

**Who might be able to join this trial:** - You have been diagnosed with Crohn's disease (affecting the small intestine, large intestine, or both) for at least 12 weeks before agreeing to take part. - Your Crohn's disease is currently mode...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01847170 — Beth Israel Deaconess Medical Center

NCT01847170 · Beth Israel Deaconess Medical Center
Completed Phase 1 Est. completion 1 November 2016
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with Crohn's disease, confirmed by a tissue biopsy, for more than 3 months - Your Crohn's disease is currently active, based on a specific symptom score used by doctors (co...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01355614 — Novartis Pharmaceuticals

NCT01355614 · Novartis Pharmaceuticals
Completed Phase 2 Est. completion 1 March 2013
🇩🇪 DE 🇨🇭 CH

**Who might be able to join this trial:** - You have at least one fistula (an abnormal tunnel) between your bowel and skin near your bottom that is actively draining - You have been officially diagnosed with Crohn's disease for at least 6 m...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01298492 — Shire

NCT01298492 · Shire
Completed Phase 2 Est. completion 27 July 2016
🇦🇹 AT 🇧🇪 BE 🇨🇦 CA 🇫🇷 FR 🇩🇪 DE

Who might be able to join this trial: - You must be between 18 and 76 years old. - You must have already taken part in one of two specific related studies (called A7281006 or A7281008) and completed the first 12 weeks of treatment, and show...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00546546 — Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

NCT00546546 · Groupe d'Etude Therapeutique des Affections Inflam...
Completed Phase 4 Est. completion 1 December 2012
🇫🇷 FR

Who might be able to join this trial: - You must be over 18 years old - You must have been diagnosed with Crohn's disease - You must have had intestinal damage or sores confirmed within the last 6 months - Your Crohn's disease must have bee...

Phase 4: Approved of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT01289366 — University of Erlangen-Nürnberg Medical School

NCT01289366 · University of Erlangen-Nürnberg Medical School
Completed Not Applicable Est. completion 1 August 2011
🇩🇪 DE

Who might be able to join this trial: - You must be willing and able to sign a consent form agreeing to take part in the trial - You must be between 18 and 85 years old - You must be able to understand what the trial involves and what it me...

Trial: NCT02227602 — Texas A&M University

NCT02227602 · Texas A&M University
Completed Not Applicable Est. completion 1 May 2017
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 79 years old (male or female) - You are currently taking a medication called mesalamine (brand names include Asacol, Apriso, Canasa, Lialda, Pentasa, or Rowasa), either as...

Trial: NCT02872376 — Fondazione IRCCS Policlinico San Matteo di Pavia

NCT02872376 · Fondazione IRCCS Policlinico San Matteo di Pavia
Completed Not Applicable Est. completion 31 December 2019
🇮🇹 IT

Who might be able to join this trial: - You have given written consent agreeing to take part in the study - You are 18 years old or older - You have been diagnosed with inflammatory bowel disease (IBD), which is a condition causing long-ter...

Trial: NCT01663142 — Centre Hospitalier Universitaire de Nice

NCT01663142 · Centre Hospitalier Universitaire de Nice
Completed Not Applicable Est. completion 1 October 2013
🇫🇷 FR

Who might be able to join this trial: - You have had surgery and need an endoscopy (a camera examination of the inside of your digestive tract) six months after your operation to check whether your condition has come back and how severe it...

Trial: NCT02108821 — Children's Mercy Hospital Kansas City

NCT02108821 · Children's Mercy Hospital Kansas City
Completed Phase 1 Est. completion 30 September 2016
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with Inflammatory Bowel Disease (IBD) — either Ulcerative Colitis (UC) or Crohn's Disease (CD) - If you have Ulcerative Colitis, your current treatment is not working well...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT03723447 — Cedars-Sinai Medical Center

NCT03723447 · Cedars-Sinai Medical Center
Completed Phase 4 Est. completion 29 October 2019
🇺🇸 US

**Who might be able to join this trial:** - You can be male or female - You are scheduled to have a major keyhole (laparoscopic) surgery on your colon or rectum - You are willing and able to read and sign a consent form agreeing to take par...

Phase 4: Approved of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT04757935 — Stanford University

NCT04757935 · Stanford University
Completed Not Applicable Est. completion 31 May 2017
🇺🇸 US

Who might be able to join this trial: - You are between 10 and 21 years old - You have been diagnosed with Crohn's Disease or Ulcerative Colitis - You are a patient of a Stanford Children's Health doctor or a pediatric gut specialist connec...

Trial: NCT03962998 — MediBeacon

NCT03962998 · MediBeacon
Completed Early Phase 1 Est. completion 5 October 2021
🇺🇸 US

**Who might be able to join this trial:** - You are over 18 years old and are male, or a female who is not pregnant or breastfeeding - You are willing to follow all the study requirements and have signed a consent form - Your heart tracing...

Early Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT04188990 — Hospital Galdakao-Usansolo

NCT04188990 · Hospital Galdakao-Usansolo
Completed Not Applicable Est. completion 30 June 2022
🇪🇸 ES

**Who might be able to join this trial:** - You are 18 years of age or older - You have been admitted to a Digestive, Oncology, or Surgery department within the last 48 hours - You have one of the following conditions: acute pancreatitis,...

Trial: NCT02856763 — Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

NCT02856763 · Groupe d'Etude Therapeutique des Affections Inflam...
Completed Not Applicable Est. completion 1 January 2020
🇫🇷 FR

Who might be able to join this trial: - You must be 18 years of age or older. - You must have been diagnosed with Crohn's disease, confirmed through tests such as endoscopy, imaging, or lab work, following standard medical guidelines. - You...